You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 29, 2024

Details for Patent: 8,247,415


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,247,415 protect, and when does it expire?

Patent 8,247,415 protects GEMTESA and is included in one NDA.

This patent has fifty-five patent family members in forty countries.

Summary for Patent: 8,247,415
Title:Hydroxymethyl pyrrolidines as .beta.3 adrenergic receptor agonists
Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of .beta.3-adrenoceptor. ##STR00001##
Inventor(s): Berger; Richard (Princeton, NJ), Chang; Lehua (Ramsey, NJ), Edmondson; Scott D. (Clark, NJ), Goble; Stephen D. (Edison, NJ), Ha; Sookhee Nicole (Warren, NJ), Kar; Nam Fung (Brooklyn, NY), Kopka; Ihor E. (Hampton, NJ), Li; Bing (Towaco, NJ), Morriello; Gregori J. (Randolph, NJ), Moyes; Chris R. (Westfield, NJ), Shen; Dong-Ming (Edison, NJ), Wang; Liping (Dayton, NJ), Zhu; Cheng (Edison, NJ)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:12/417,239
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 8,247,415

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Urovant GEMTESA vibegron TABLET;ORAL 213006-001 Dec 23, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,247,415

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 072043 ⤷  Try a Trial
Austria E535521 ⤷  Try a Trial
Australia 2009231714 ⤷  Try a Trial
Brazil PI0909768 ⤷  Try a Trial
Canada 2719876 ⤷  Try a Trial
Chile 2009000815 ⤷  Try a Trial
China 102056917 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.